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ABSTRACT CC chemokine receptor 2 (CCR2) is a prom-
inent receptor for the monocyte chemoattractant protein
(MCP) group of CC chemokines. Mice generated by gene
targeting to lack CCR2 exhibit normal leukocyte rolling but
have a pronounced defect in MCP-1-induced leukocyte firm
adhesion to microvascular endothelium and reduced leuko-
cyte extravasation. Constitutive macrophage trafficking into
the peritoneal cavity was not significantly different between
CCR2-deficient and wild-type mice. However, after intraperi-
toneal thioglycollate injection, the number of peritoneal mac-
rophages in CCR2-deficient mice did not rise above basal
levels, whereas in wild-type mice the number of macrophages
at 36 h was '3.5 times the basal level. The CCR2-deficient
mice showed enhanced early accumulation and delayed clear-
ance of neutrophils and eosinophils. However, by 5 days
neutrophils and eosinophils in both CCR2-deficient and wild-
type mice had returned to near basal levels, indicating that
resolution of this inf lammatory response can occur in the
absence of macrophage inf lux and CCR2-mediated activation
of the resident peritoneal macrophages. After intravenous
injection with yeast b-glucan, wild-type mice formed numer-
ous large, well-defined granulomas throughout the liver pa-
renchyma, whereas CCR2-deficient mice had much fewer and
smaller granulomas. These results demonstrate that CCR2 is
a major regulator of induced macrophage trafficking in vivo.
Accumulation of leukocytes at inflammatory sites is regulated
by a family of small, discrete chemotactic proteins called
chemokines (1, 2). Two major chemokine subfamilies are
distinguished by whether the first two conserved cysteine
residues occur together (CC) or are separated by another
amino acid (CXC). The monocyte chemoattractant proteins
(MCPs) share about 65% amino acid identity and comprise a
subgroup within the CC chemokine subfamily (3–5). MCP-1 is
the most prominent and best studied of these molecules.
MCP-1 is produced by a wide variety of cell types in response
to pro-inflammatory stimuli (1, 6, 7), and its chemotactic and
activating functions are directed at monocytes, T lymphocytes,
natural killer (NK) cells and basophils (8–14).
The CC chemokine receptors (CCRs) are structurally re-
lated, seven-transmembrane-spanning proteins that signal
through heterotrimeric G-protein complexes (15). In the
mouse, MCP-1 appears to bind solely to CCR2 (16), although
CCR2 also serves as a receptor for the other MCP subfamily
members (17–20). CCR2 gene expression is highly regulated.
Differentiation of monocytes to macrophages or treatment of
monocytes with interferon g, tumor necrosis factor a plus
interleukin 1, or with lipopolysaccharide decreases CCR2 gene
transcription whereas interleukin 2 treatment of T lympho-
cytes and monocytes augments CCR2 expression (21–24).
MCP-1, the major ligand for CCR2, is abundantly expressed
in a number of pathological conditions characterized by mono-
cyte infiltration, including atherosclerosis (25, 26), rheumatoid
arthritis (27, 28), experimental autoimmune encephalomyelitis
(29, 30), idiopathic pulmonary fibrosis (31), psoriasis (32),
glomerulonephritis (33), and allograft rejection (34). With
respect to HIV-1 infection and AIDS, CCR2 can serve as a
coreceptor for some HIV-1 strains (35); however, a point
mutation in the CCR2 gene that leads to a single, conservative
amino acid change in the first transmembrane domain of
CCR2 was found to correlate with significantly delayed pro-
gression to AIDS (36).
To determine the in vivo biological functions of CCR2 and
the potential consequences of chronic CCR2 deficiency, we
used homologous recombination in embryonic stem (ES) cells
to disrupt expression of the mouse CCR2 gene. Our results
demonstrate that CCR2 deficiency severely diminishes leuko-
cyte adhesion to the microvasculature and monocyte extrav-
asation in response to pro-inflammatory stimuli.
MATERIALS AND METHODS
Cloning and Targeted Disruption of the Mouse CCR2 Gene.
A 748-bp PCR fragment was made from human genomic DNA
using primers corresponding to unique regions of the human
CCR2 gene: 59-GCTTTCACAGTTACTCAGGCCGAA-39
and 59-CATAAATTTGACGTGAAGCAA-39 (37). This
fragment was radiolabeled with [a-32P]dCTP and used to
screen mouse strain 129yOla genomic libraries. A single clone
was identified that contained a 2.6-kb EcoRI fragment which
included 60% of the N-terminal coding sequence for mouse
CCR2 (16, 18) and upstream sequences. Alignment of the
mouse CCR2 genomic sequence with the cDNA sequence
revealed a splice site 11 bp in front of the putative translation
start codon and a noncoding exon located '2 kb upstream of
the coding exon. The 2.6-kb EcoRI fragment cloned in pBlue-
script served as the basis for the construction of a targeting
plasmid (see Fig. 1).
Control Animals. Southern blot analysis of bacterial artifi-
cial chromosome (BAC) clones containing large (50–240 kb)
fragments of strain 129 genomic DNA indicated that the
CCR1, CCR2, and CCR5 genes are closely linked (ref. 16 and
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our unpublished results), consistent with the clustering of
human CCR genes (39). To eliminate the potential influence
of strain-specific effects linked to the CCR2 gene (40), a
control strain in which the CCR gene cluster is derived from
the 129yOla strain was developed by crossing wild-type F1
progeny of 129yOla 3 C57BLy6J matings (40). A BglII
restriction fragment length polymorphism was found that
distinguishes the CCR5 allele in 129yOla and C57BLy6J; a
probe made from a 1.5-kb XbaI fragment located about 1.8 kb
upstream of the CCR5 coding exon detects a 3.3-kb BglII
fragment in 129yOla and a 3.6-kb BglII fragment in C57BLy6J
genomic DNA. All work with animals was done in accordance
with National Institutes of Health guidelines and protocols
approved by Animal Care and Use Committees at the Uni-
versity of North Carolina at Chapel Hill, the University of
Texas at Austin, and the University of Virginia.
Competitive Binding Assays. Radioiodinated mouse JE (an
MCP family member and a ligand for CCR2) was purchased
from New England Nuclear. To obtain macrophages for
binding assays, mice 8–12 weeks old were injected i.p. with 1
ml of 4% Brewers thioglycollate broth (Becton Dickenson).
Three days later mice were killed by exposure to CO2 and the
peritoneal cells were harvested by lavage with 7 ml of PBS.
Cells were counted with a hemocytometer. Binding assays
were done in duplicate in round-bottom 96-well plates and a
final volume of 200 ml. Binding buffer was RPMI 1640
medium, 40 mM Hepes (pH 7.5), and 1% BSA. Two-fold serial
dilutions of cold JE (R & D Systems) were made beginning at
a final concentration of 10 nM and radiolabeled chemokine
was added at a final concentration of 0.2 nM. After addition
of cells, the plates were incubated for 3 h at 4°C, at which time
bound ligand was separated from free by briefly microcentri-
fuging the cells through 100 ml of a mixture of 80% dibu-
tylphthalatey20% olive oil. The tubes were frozen and the cell
pellets were clipped into counting tubes. Both cell-associated
and free radioactivity were measured in a gamma counter.
PRISM software (Graphpad, San Diego) was used for calcula-
tions, statistical analysis, and graphics.
Intravital Microscopy. Intravital microscopy of the mouse
cremaster muscle was performed as described (41). Briefly,
mice were anesthetized by i.p. injection with 30 mgykg sodium
pentobarbital (Nembutal; Abbott) and 0.1 mgykg atropine
(Elkins–Sinn, Cherry Hill, NJ), followed by 100 mgykg ket-
amine hydrochloride (Ketalar; Parke-Davis). All mice were
pretreated for 2 h before surgery with an intrascrotal injection
of 300 ng recombinant murine MCP-1 (PharMingen) in 0.3 ml
isotonic saline, the dose sufficient to induce significant leu-
kocyte adhesion in wild-type mice. The trachea, carotid artery,
and jugular vein were cannulated for blood sampling, blood
pressure monitoring, and injection of supplemental anesthetic.
The cremaster was dissected as described (41) and placed on
an intravital microscope (Axioskop; Carl Zeiss) with a saline
immersion objective (SW 40, 0.75 numerical aperature).
Venules with diameters between 20 and 60 mm were recorded
through a charged-coupled device (CCD) camera system
(model VE-1000CD; Dage–MTI, Michigan City, IN) on an
S-VHS video recorder. Microvessel diameters were measured
from video recordings using a customized digital image pro-
cessing system (42). The centerline erythrocyte velocity in
recorded microvessels was measured using a dual photodiode
and a digital on-line cross-correlation program (42) running on
an IBM-compatible computer system. Centerline velocities,
Vc, were converted to mean blood flow velocities, Vb, by
dividing the centerline velocity by an empirical factor of 1.6
(43). Wall shear rates were estimated as 2.12 (8 Vbyd), where
Vb is the mean blood flow velocity, d is the diameter of the
vessel, and 2.12 is a median empirical correction factor ob-
tained from actual velocity profiles measured in microvessels
in vivo (44). The venules were stratified for a similar distribu-
tion of hemodynamic parameters (wall shear rate range be-
tween 400 and 1,500 s21). In these venules, the number of
adherent leukocytes was determined per 200 mm segment of
venule from the intravital video recordings. For differential
counts, whole mount preparations were prepared as described
(45) and emigrated leukocytes were counted in a semicircular
field of view. The velocity of rolling leukocytes was determined
by measuring the distance traveled during a constant 2-s time
interval. A constant time interval was chosen because previous
research had indicated that varying time intervals of velocity
measurements can introduce experimental artifacts (46). The
mean rolling velocities and numbers of adherent or emigrated
leukocytes were compared between genotypes using the two-
tailed Student’s t test with correction for unequal variances.
Statistical significance was set at P , 0.01.
Cytospin Preparations. Peritoneal exudate cells were har-
vested at various times after thioglycollate injection, counted,
and cytospun onto slides using a cytocentrifuge (StatSpin;
Shandon Scientific, Runcorn, U.K.). Cells were stained with
Diff-Quik (Baxter Scientific Products, McGaw Park, IL) and
leukocyte differentials were determined by scoring at least 300
cells. Peripheral blood was obtained from the retro-orbital
sinus using heparinized capillary tubes. Red blood cells were
lysed by using an erythrocyte lysis kit (R & D Systems). White
blood cells were counted with a hemocytometer, cytospun
onto slides and stained with Diff-Quick. Statistics were calcu-
lated as described above.
Liver Granulomas and Histology. Groups of 6- to 12-week-
old mice were given a single tail vein injection of 200 ml of PBS
containing 2 mg of sonicated Zymocel, a purified yeast b-
glucan preparation composed of nonantigenic micron-sized
particles (Alpha-Beta Technology, Pullman, WA). After 10
days, the peak time for hepatic granuloma formation, the mice
were sacrificed by exposure to CO2 and the livers were excised
intact and fixed in Bouin’s solution. Sections were cut and
stained with hematoxylinyeosin. Slides were examined under a
light microscope at various magnifications.
RESULTS
Targeted Disruption of the Mouse CCR2 Gene. The target-
ing strategy used to disrupt CCR2 gene expression is shown in
Fig. 1A. The neomycin-resistance cassette was inserted in front
of the coding sequence for the first transmembrane domain of
CCR2 in opposite transcriptional orientation (16, 18). Male
chimeras generated from correctly targeted ES cells transmit-
ted the mutation through the germ line when mated with
C57BLy6J females (Fig. 1B). Heterozygote matings then pro-
duced homozygous CCR22y2 mice at the expected Mende-
lian frequency. The CCR22y2 mice were viable, exhibited
normal growth and development and were fertile. In compet-
itive binding assays using 125I-labeled JE, thioglycollate-
elicited peritoneal exudate cells from CCR22y2 mice showed
a dramatic reduction in specific binding relative to the elicited
cells from control animals (Fig. 1C). The CCR22y2 mice have
been observed for up to 15 months in both pathogen-free
conditions and in viral-free conventional caging without ob-
servable differences with wild-type mice, suggesting that they
are not severely immunocompromised.
Defective Leukocyte Adhesion to the Microvasculature.
Current models of induced leukocyte extravasation propose a
multistep process that includes rolling of leukocytes along the
vessel wall, firm adhesion, and arrest at sites of high chemoat-
tractant concentration, transendothelial cell migration, and
chemotaxis (47). We therefore compared leukocyte rolling in
venules of MCP-1-treated cremaster muscle of CCR2-deficient
and wild-type mice. The numbers of rolling cells per unit of
time and the distribution of rolling velocities were not different
between the two groups (Fig. 2) and are similar to those seen
without MCP-1 treatment (45). This finding shows that the
rolling of the majority of leukocytes is unaffected by a defi-
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ciency in CCR2, although our data do not exclude the possi-
bility that the rolling velocity of a small subpopulation of
circulating leukocytes—e.g., monocytes or NK cells—might be
altered in CCR2-deficient mice.
In contrast to these results with rolling, the number of firmly
adherent leukocytes inside cremaster muscle venules was
significantly reduced (P , 0.01) in CCR2-deficient mice after
MCP-1 treatment (Fig. 3A). This reduction in leukocyte
adhesion was accompanied by a diminished accumulation of
leukocytes in the tissue space surrounding the venules (Fig.
3B). Whereas in wild-type mice an average of 32 cells was
found next to a venule in a high power microscopic field, an
average of only 20 cells was observed in CCR2-deficient
animals (P , 0.01). These differences could not be attributed
to differences in hemodynamic parameters between the
venules in wild-type and CCR2-deficient mice as judged by our
finding no significant differences in diameter, centerline ve-
locity, and shear rate in the two types of mice (data not shown).
Induced But Not Constitutive Monocyte Accumulation Is
Severely Reduced in CCR2-Deficient Mice. An i.p. injection of
thioglycollate is a well-established mouse model of acute
peritonitis, which is characterized by successive waves of
granulocyte and macrophage accumulation. To determine
whether CCR2 deficiency affects this dynamic inflammatory
process, control and CCR2-deficient mice were injected with
thioglycollate and the number and type of leukocytes present
in the peritoneal cavity at 4, 24, 36, 72, and 120 h after injection
were determined. As shown in Fig. 4, the absence of CCR2 led
to multiple changes in leukocyte accumulation. In both wild-
type and CCR2-deficient mice, the vast majority of resident
peritoneal leukocytes were macrophages, and 4 h after thio-
glycollate injection, the number of macrophages in both strains
was decreased by .40% (Fig. 4A). After this time point,
however, the two strains differed dramatically in number of
peritoneal macrophages. By 24 h, the macrophages in wild-type
mice were '2 times basal levels, peaked at 36 h at 3.5 times
basal levels, and then declined at 72 h and 120 h, at which time
after thioglycollate injection of CCR21y1 (■) and CCR22y2 (Œ)
animals. Cells (1.7 3 106 cells per well) were incubated with 0.2 nM
labeled JE, and the indicated concentration of unlabeled JE for 3 h at
4°C. Each data point represents the average of duplicate determina-
tions of bound labeled JE. In the experiment shown, the CCR22y2
cells exhibited a 93% reduction in specific binding (72% after nor-
malization for the number of macrophages in the cell populations; see
text). In three similar experiments, the mean 6 SEM reduction in
binding was 89.1 6 3.5%.
FIG. 1. Strategy for targeted disruption of the mouse CCR2 gene.
(A) (Top) CCR2 gene locus showing the single coding exon on a 5.0-kb
BglII (Bg) fragment and a noncoding exon about 2 kb upstream of the
coding exon. Other restriction enzyme sites are XbaI (X), BamHI
(Bm), and EcoRI (E). A 420-bp PCR fragment of the 39 coding region
of the cross-hybridizing CCR5 gene was used as a probe to screen for
correctly targeted ES clones and to detect germ-line transmission of
the mutation. Probe A was used to confirm correct recombination at
the 59 end. (Middle) The targeting plasmid. A 1.8-kb pgk-neo cassette
was then inserted into the unique BamHI site in the CCR2 coding
region. This insertion created homology arms of 2.0 kb and 0.6 kb. A
pgk-thymidine kinase (TK) cassette on a KpnI fragment was inserted
into the KpnI site of the pBluescript polylinker. The targeting plasmid
was linearized by digestion with NotI, transfected by electroporation
into E14TG2a ES cells (38), and the transfected cells were placed
under double selection in 200 mgyml G418 and 2 mM ganciclovir.
(Bottom) Structure of the correctly targeted allele. There is a unique
BglII site near the 39 end of the neo gene which results in a reduction
of the germ-line 5.0-kb BglII fragment to 3.7 kb when the CCR5 probe
is used and 3.1 kb when probe A is used. (B) Southern blot showing
correct targeting and germ-line transmission of the mutation.
Genomic DNA was prepared from mouse strain 129yOla liver, the
correctly targeted ES clone 20-5y17 used for blastocyst injection, and
from the tails of F1 1y2 heterozygote, F2 homozygote 1y1, and F2
homozygote 2y2 mice. The DNA was digested with BglII and probed
with the CCR5 coding region PCR fragment, detecting bands of 5.0 kb
(wild-type CCR2 fragment), 3.7 kb (mutant CCR2 fragment), and 1.6
kb (wild-type CCR5 fragment). (C) Competitive binding assay using
125I-labeled murine JE on peritoneal exudate cells harvested 3 days
FIG. 2. Rolling leukocyte velocities measured in venules of the
exposed cremaster muscle treated with MCP-1 for 3 h. The rolling
velocities (in mmys) of 214 leukocytes in CCR21y1 mice (gray bars)
and 178 leukocytes in CCR22y2 mice (black bars) were measured
and showed a similar distribution.
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macrophage numbers were about 1.5 times the basal level. In
contrast, the peritoneal macrophages in the CCR2-deficient
mice never rose above the constitutive level at any time point,
and at 120 h the number of macrophages was only about 17%
of the constitutive number. The differences between control
and CCR2-deficient mice were significant (P , 0.01 at 24, 36,
and 120 h and P , 0.001 at 72 h) and clearly demonstrate that
CCR2 is essential for macrophage migration in this model of
acute inflammation.
Neutrophils and eosinophils comprise only about 2% of the
resident peritoneal leukocytes in both mouse strains, but after
thioglycollate injection, the two strains again showed different
patterns of accumulation and clearance (Fig. 4B). In both
strains there was a large influx of neutrophils and eosinophils
at 4 h but the CCR2-deficient mice showed a mean of 40%
more cells than control animals. Peak accumulation, '75 times
basal levels in both strains, was reached at 24 h. Neutrophils
and eosinophils declined sharply in control mice at 36 and 72 h,
but they remained elevated in the CCR2-deficient mice until
the 120-h time point. At both the 36- and 72-h time points the
differences in cell number were significant (P , 0.001). By
120 h both strains had returned to '5 times basal level.
Because MCP-1 does not have a direct effect on neutrophil and
eosinophil chemotaxis (1), these differences could be related
to the reduced macrophage numbers or to effects on another
cell type.
Lymphocytes and granulated basophils together account for
,5% of peritoneal leukocytes (Fig. 4 C and D). After thio-
glycollate injection, changes in these cell populations followed
clearly distinct trends in wild-type and CCR22y2 mice.
Control mice showed a substantial early increase in lympho-
cytes at 4 h, reaching a peak at 24 h of 2.6 times the basal level
(Fig. 4C). CCR2-deficient animals did not have this early
increase but showed a 4.5-fold increase at 36 h. In both cases
lymphocytes returned to approximately basal levels by 120 h.
Both strains had similar constitutive numbers of basophils (Fig.
4D). After thioglycollate injection, control animals showed a
gradual reduction in basophilic cells at each time point and by
120 h only about 15% of the constitutive number remained.
CCR2-deficient mice showed a reduction in basophils of 55%
at 4 h, but no further decline through 120 h. The results
summarized in Fig. 4 demonstrate that CCR2 deficiency,
either directly or indirectly, alters the accumulation of multiple
leukocyte subtypes in this acute inflammatory process.
Reduced Liver Granuloma Formation in CCR22y2 Mice.
Previous studies by others have shown that 10 days after i.v.
injection of yeast glucan, about 10% of the total liver paren-
chymal volume becomes granulomatous, with the typical lesion
consisting predominantly of macrophage-derived cells (48, 49).
Because MCP-1 has been implicated in hepatic and pulmonary
granuloma formation (50, 51), we assessed granuloma forma-
tion in the livers of control and CCR2-deficient mice after
intravenous injection of the b-glucan extract Zymocel. The
livers of uninjected mice showed no evidence of granuloma
formation. Ten days after glucan injection of control mice,
numerous (.50y3100 microscope field) large, well-
circumscribed granulomas had developed throughout the liver
parenchyma (data not shown). These were composed mainly
of epithelioid histiocytes with occasional polymorphonuclear
cells (Fig. 5A). In contrast, the livers of CCR2-deficient mice
did not show these large granulomas, but instead had fewer
(,10y3100 microscopic field) small cellular foci consisting of
only a few histiocytes and polymorphonuclear cells. In addition
to these small foci, the CCR2-deficient mice also had occa-
sional (1–2y3100 microscopic field), larger necrotising gran-
FIG. 4. Peritoneal leukocyte accumulation in CCR21y1 mice
(gray bars) and CCR22y2 mice (black bars) following thioglycollate
injection. The number of each leukocyte type was determined on
cytospin slides at the times indicated after thioglycollate injection: (A)
Mac, macrophages; (B) N1E, neutrophils and eosinophils; (C) Lym,
lymphocytes; (D) Bas, granulated basophils (n $ 5 CCR21y1 and
CCR22y2 animals at each time point. Data are presented as mean 6
SEM; significant difference: p, P , 0.01; †, P , 0.001. Differences in
C and D did not reach statistical significance.
FIG. 3. (A) Leukocyte adhesion, measured as firmly adherent cells
per 200-mm segment of venule. A total of 368 cells in 16 venules
adhered in CCR21y1 mice (gray bar) and 246 cells in 19 venules
adhered in CCR22y2 mice (black bar). In mice receiving saline only,
fewer than two adherent leukocytes were observed per venule. (B)
Leukocyte emigration, expressed as number of cells emigrated per
venule. A total of 493 cells were observed next to 31 venules of
CCR21y1 mice (gray bar) and 323 cells were observed next to 31
venules of CCR22y2 mice (black bar). No emigrated leukocytes were
seen in mice receiving saline only. Data are presented as mean 6 SEM.
Significant difference: p, P , 0.01.
FIG. 5. Differences in glucan-induced hepatic granuloma forma-
tion in wild-type and CCR2-deficient mice. (A) A typical large,
well-defined granuloma consisting predominantly of epithelioid his-
tiocytes and a few polymorphonuclear cells found in the livers of
wild-type but not CCR22y2 mice after intravenous glucan injection.
(B) One of the small number of well-formed necrotising granulomas
consisting of polymorphonuclear cells found in the livers of glucan-
injected CCR2-deficient mice. (3330.)
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ulomas composed primarily of polymorphonuclear cells (Fig.
5B).
DISCUSSION
Blocking MCP-1 binding to CCR2 has been proposed as a
possible intervention to reduce the pathological sequelae
caused by the accumulation of macrophages and T cells that
occurs during the course of some diseases. Mice deficient in
CCR2 provide a means of determining whether this strategy
can provide therapeutic benefits and can help ascertain the
potential negative effects of this strategy on normal immune
processes. We find that CCR2 deficiency has no observable
effects on growth, development, or fertility, and that it does not
result in significant reductions in constitutive accumulation of
peritoneal macrophages (Fig. 4), Kupffer cells, and alveolar
macrophages (R. Alam and W.A.K., unpublished observa-
tions). However, the biological consequences of CCR2 defi-
ciency in mice become clear when the animals are challenged
with pro-inflammatory stimuli.
Our results with intravital microscopy indicate that CCR2 is
not required for the rolling of leukocytes in the presence of
MCP-1. However, it is important for firm adhesion to the
endothelium and subsequent diapedesis. The finding that both
processes are similarly reduced suggests that the reduction in
leukocyte passage through the endothelium is only a reflection
of the reduced firm adhesion and that the ability of CCR2-
negative adherent cells to transmigrate is not impaired.
The dramatic reductions in macrophage accumulation in the
peritonitis model and hepatic granuloma assay clearly dem-
onstrate that CCR2 is important for induced macrophage
trafficking, although we cannot exclude the presence of a low
level of induced macrophage migration into the peritoneal
cavity or liver that is CCR2 independent. For example, the
small, histiocyte-containing cell foci in the livers of our glucan-
injected CCR2-deficient mice might have arisen from a small
subpopulation of CCR2-independent macrophages.
Which of the MCPs is the major stimulus for CCR2-
dependent macrophage accumulation in the peritonitis model
and granuloma assay is not yet established, but our current
data make MCP-1 a strong candidate. Neutrophils and eosin-
ophils have the ability to produce MCP-1 (52–54), and they
accumulate in the peritoneal cavity of normal animals treated
with thioglycollate prior to macrophage recruitment. High
peritoneal MCP-1 concentrations generated by these cells
would likely lead to basophil degranulation (9–11), contrib-
uting to the observed steady reduction in basophilic cells in
control animals. The absence of this reduction in basophils in
the CCR22y2 animals would then be understood.
Phagocytosis of intact neutrophils and eosinophils that have
accumulated at inflammatory sites and the efficient resolution
of inflammatory responses are important macrophage func-
tions (55). The prolonged or excessive presence of activated
neutrophils and eosinophils can contribute to the damage of
normal tissues through the release of oxygen intermediates,
proteolytic enzymes and pro-inflammatory cytokines (56–58).
Several modes of inflammatory cell clearance have been
identified that would avoid the release of these substances,
including apoptosis followed by macrophage engulfment (59,
60), phagocytosis without apoptosis (61), and emigration out
of the inflammatory site (62). We observed the characteristic
features of apoptotic granulocytes (63, 64) in the cytospins of
freshly harvested peritoneal exudate cells from both wild-type
and CCR2-deficient mice at all time points after thioglycollate
injection (data not shown), although the proportion of cells
showing these features was low. The time course data in Fig.
4B show that most of the accumulated neutrophils and eosin-
ophils have disappeared by 5 days irrespective of the strain, yet
the CCR2-deficient mice have relatively few resident perito-
neal macrophages and do not recruit large numbers of new
macrophages. Possibly, therefore, emigration may be largely
responsible for the sharp drop in granulocytes that occurs
between 36 and 72 h in the mutant animals. However, our data
do not exclude the contribution of multiple clearance mech-
anisms contributing to resolving the peritonitis.
In conclusion, we have found that CCR2-deficient mice have
no obvious phenotypic defects and are not severely immuno-
compromised. The mutant mice are not significantly different
from wild-type animals in leukocyte rolling and constitutive
macrophage accumulation, but they do exhibit dramatic re-
ductions in induced leukocyte firm adhesion, extravasation,
and macrophage accumulation in vivo. Our results support the
idea that specific blockers of CCR2 might provide significant
therapeutic benefit without severe side effects in pathological
conditions characterized by MCP-1 production and subse-
quent mononuclear cell infiltration (65). The CCR2-deficient
mouse should provide a valuable tool for studying the patho-
genesis of inflammatory diseases and for determining which
conditions might improve or be exacerbated by antagonists of
CCR2 ligands.
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